Tyme Technologies Inc., an emerging biotechnology company developing cancer metabolism-based therapies, closed an underwritten registered offering on April 2, 2019, resulting in gross proceeds of approximately $12 million. Our firm represented Tyme in the offering.
Tyme registered the offering of 8 million shares of its common stock, par value $0.0001 per share, and of warrants to purchase 8 million shares of its common stock at a combined purchase price of $1.50 per share of common stock and accompanying warrant. Canaccord Genuity LLC acted as sole bookrunning manager for the offering and H.C. Wainwright & Co., LLC acted as lead manager.
Tyme’s shares trade on the NASDAQ Global Market under the symbol “TYME.”
